Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
Conditions
Brief summary
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Detailed description
The study was designed to evaluate the efficacy and safety of different forms of neoadjuvant intense androgen deprivation therapy (ADT) compared with ADT alone, followed by prostatectomy.
Interventions
DRUGADT
The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.
DRUGAbiraterone Acetate
1000 mg (250 mg×4 tablets) once daily, orally
5 mg once daily, orally.
DRUGEnzalutamide
160 mg (40 mg× 4 tablets) once daily, orally.
DRUGApalutamide
240 mg (60 mg×4 tablets) once daily, orally.
DRUGDarotamide
600 mg (300 mg × 2 tablets) twice daily, orally.
DRUGRezvilutamide
240 mg (80 mg × 3 tablets) once daily orally
DRUGPARP inhibitor
The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.
PROCEDURERobot-assisted radical prostatectomy
Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. All patients must have been histologically diagnosed of prostate cancer and must be eligible for radical prostatectomy. 2. All patients must undergo thorough tumor staging and meet one of the following criteria: a) multi-parameter MRI or PSMA PET/CT shows clinical staging of primary tumor ≥ T3; b) Gleason score of primary tumor ≥ 8; c)prostate specific antigen(PSA) ≥20 ng/ml; d) Imaging evaluation shows regional lymph node metastases (N1). 3. Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1. 4. Patients must have adequate hematologic function, hepatic function, renal function and cardiac function. 5. Patients must participate voluntarily and sign an informed consent form(ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must bewilling to obey the prohibitions and restrictions specified in the research protocol. 6. Fertile patients must be willing to use highly effective contraception during the study period and within 120 days of the last dose of treatment.
Exclusion criteria
1. Patients with neuroendocrine, small cell, or sarcoma-like pathologic features are not eligible. 2. Patients with low-risk or medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: a) multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor \< T3; b) Gleason score of primary tumor \< 8; c) prostate specific antigen (PSA) \<20 ng/ml. 3. Patients with clinical or radiological evidence of extra-regional lymph node metastases or bone metastases or visceral metastases (any M1) are not eligible. 4. Patients who have previously received androgen deprivation therapy (medical or surgical) or focal treatment, radiotherapy, chemotherapy for prostate cancer are not eligible. 5. Patients with severe or uncontrolled concurrent infections are not eligible. 6. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration. 7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection. 8. Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled. 9. Patients with mental illness, mental disability or inability to give informed consent are not eligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathologic response rate | up to 3 years | Pathologic response rate= Pathologic Complete Response (pCR) Rate + Minimal Residual Disease (MRD) rate |
| 3 year biochemical progression free survival (bPFS) | up to 3 years | Biochemical progression free survival (bPFS) within 3 years |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PSA response rate | up to 3 years | Prostate specific antigen (PSA) drops ≥ 98% after intense neoadjuvant therapy |
| Positive margin rate | up to 6 months | The positive margin rate of whole-mount pathology for prostatectomy after intense neoadjuvant therapy |
| Metastasis-Free Survival (MFS) | up to 5 years | Metastasis-Free Survival (MFS) after intense neoadjuvant therapy |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | up to 5 years | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0. All grades of adverse events will be documented. |
| Pathologic downgrade rate | up to 6 months | The pathologic downgrade rate of whole-mount pathology for prostatectomy after intense neoadjuvant therapy compared with initial T stage. |
| Time to castration-resistant prostate cancer（CRPC) | up to 5 years | Time to castration-resistant prostate cancer（CRPC) after intense neoadjuvant therapy |
Countries
China
Outcome results
None listed